

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Virotherapy: cancer gene therapy at last? | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/5-2105/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/5-2105" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Virotherapy: cancer gene therapy at last?" />
    
            <meta name="og:title" content="F1000Research Article: Virotherapy: cancer gene therapy at last?.">
            <meta name="og:description" content="Read the latest article version by Alan E.  Bilsland, Pavlina Spiliopoulou, T. R. Jeffry Evans, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="8831">
            <meta name="article-id" content="8211">
            <meta name="dc.title" content="Virotherapy: cancer gene therapy at last?">
            <meta name="dc.description" content="For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach. However, steady progress in vector development and accumulated experience from previous clinical studies has finally led the field to its first licensed therapy. Following a pivotal phase III trial, Imlygic (talimogene laherparepvec/T-Vec) received US approval as a treatment for cutaneous and subcutaneous melanoma in October 2015, followed several weeks later by its European authorisation. These represent the first approvals for an oncolytic virotherapy. Imlygic is an advanced-generation herpesvirus-based vector optimised for oncolytic and immunomodulatory activities. Many other oncolytic agents currently remain in development, providing hope that current success will be followed by other diverse vectors that may ultimately come to constitute a new class of clinical anti-cancer agents. In this review, we discuss some of the key oncolytic viral agents developed in the adenovirus and herpesvirus classes, and the prospects for further enhancing their efficacy by combining them with novel immunotherapeutic approaches.">
            <meta name="dc.subject" content="Cancer gene therapy, oncolytic virus, adenovirus, herpesvirus, cancer immunotherapy, Imlygic, ">
            <meta name="dc.creator" content="Bilsland, Alan E. ">
            <meta name="dc.creator" content="Spiliopoulou, Pavlina">
            <meta name="dc.creator" content="Evans, T. R. Jeffry">
            <meta name="dc.date" content="2016/08/30">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.8211.1">
            <meta name="dc.source" content="F1000Research 2016 5:2105">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Cancer gene therapy ">
            <meta name="prism.keyword" content=" oncolytic virus ">
            <meta name="prism.keyword" content=" adenovirus ">
            <meta name="prism.keyword" content=" herpesvirus ">
            <meta name="prism.keyword" content=" cancer immunotherapy ">
            <meta name="prism.keyword" content=" Imlygic ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2016/08/30">
            <meta name="prism.volume" content="5">
            <meta name="prism.number" content="2105">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.8211.1">
            <meta name="prism.url" content="https://f1000research.com/articles/5-2105">
            <meta name="citation_title" content="Virotherapy: cancer gene therapy at last?">
            <meta name="citation_abstract" content="For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach. However, steady progress in vector development and accumulated experience from previous clinical studies has finally led the field to its first licensed therapy. Following a pivotal phase III trial, Imlygic (talimogene laherparepvec/T-Vec) received US approval as a treatment for cutaneous and subcutaneous melanoma in October 2015, followed several weeks later by its European authorisation. These represent the first approvals for an oncolytic virotherapy. Imlygic is an advanced-generation herpesvirus-based vector optimised for oncolytic and immunomodulatory activities. Many other oncolytic agents currently remain in development, providing hope that current success will be followed by other diverse vectors that may ultimately come to constitute a new class of clinical anti-cancer agents. In this review, we discuss some of the key oncolytic viral agents developed in the adenovirus and herpesvirus classes, and the prospects for further enhancing their efficacy by combining them with novel immunotherapeutic approaches.">
            <meta name="citation_description" content="For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach. However, steady progress in vector development and accumulated experience from previous clinical studies has finally led the field to its first licensed therapy. Following a pivotal phase III trial, Imlygic (talimogene laherparepvec/T-Vec) received US approval as a treatment for cutaneous and subcutaneous melanoma in October 2015, followed several weeks later by its European authorisation. These represent the first approvals for an oncolytic virotherapy. Imlygic is an advanced-generation herpesvirus-based vector optimised for oncolytic and immunomodulatory activities. Many other oncolytic agents currently remain in development, providing hope that current success will be followed by other diverse vectors that may ultimately come to constitute a new class of clinical anti-cancer agents. In this review, we discuss some of the key oncolytic viral agents developed in the adenovirus and herpesvirus classes, and the prospects for further enhancing their efficacy by combining them with novel immunotherapeutic approaches.">
            <meta name="citation_keywords" content="Cancer gene therapy, oncolytic virus, adenovirus, herpesvirus, cancer immunotherapy, Imlygic, ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Alan E.  Bilsland">
            <meta name="citation_author_institution" content="Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Glasgow, G61 1QH, UK">
            <meta name="citation_author" content="Pavlina Spiliopoulou">
            <meta name="citation_author_institution" content="Beatson West of Scotland Cancer Centre, Glasgow, G12 OYN, UK">
            <meta name="citation_author" content="T. R. Jeffry Evans">
            <meta name="citation_author_institution" content="Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Glasgow, G61 1QH, UK">
            <meta name="citation_publication_date" content="2016/08/30">
            <meta name="citation_volume" content="5">
            <meta name="citation_publication_number" content="2105">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.8211.1">
            <meta name="citation_firstpage" content="2105">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/5-2105/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/5-2105.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=8831 /> <input type=hidden id=articleId name=articleId value=8211 /> <input type=hidden id=xmlUrl value="/articles/5-2105/v1/xml"/> <input type=hidden id=xmlFileName value="-5-2105-v1.xml"> <input type=hidden id=article_uuid value=2b3ff30f-05fd-4fc8-848a-bf49b3545914 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Virotherapy: cancer gene therapy at last?"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.8211.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.8211.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/5-2105"
  },
  "headline": "Virotherapy: cancer gene therapy at last?",
  "datePublished": "2016-08-30T16:13:31",
  "dateModified": "2016-08-30T16:13:31",
  "author": [
    {
      "@type": "Person",
      "name": "Alan E.  Bilsland"
    },    {
      "@type": "Person",
      "name": "Pavlina Spiliopoulou"
    },    {
      "@type": "Person",
      "name": "T. R. Jeffry Evans"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach. However, steady progress in vector development and accumulated experience from previous clinical studies has finally led the field to its first licensed therapy. Following a pivotal phase III trial, Imlygic (talimogene laherparepvec/T-Vec) received US approval as a treatment for cutaneous and subcutaneous melanoma in October 2015, followed several weeks later by its European authorisation. These represent the first approvals for an oncolytic virotherapy. Imlygic is an advanced-generation herpesvirus-based vector optimised for oncolytic and immunomodulatory activities. Many other oncolytic agents currently remain in development, providing hope that current success will be followed by other diverse vectors that may ultimately come to constitute a new class of clinical anti-cancer agents. In this review, we discuss some of the key oncolytic viral agents developed in the adenovirus and herpesvirus classes, and the prospects for further enhancing their efficacy by combining them with novel immunotherapeutic approaches."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/5-2105/v1",
            "name": "Virotherapy: cancer gene therapy at last?"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Virotherapy: cancer gene therapy at last? </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=8831 data-id=8211 data-downloads="" data-views="" data-scholar="10.12688/f1000research.8211.1" data-recommended="" data-doi="10.12688/f1000research.8211.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/5-2105/v1/pdf?article_uuid=2b3ff30f-05fd-4fc8-848a-bf49b3545914" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-8211-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-8211-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-8211-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Bilsland AE, Spiliopoulou P and Evans TRJ. Virotherapy: cancer gene therapy at last? [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2105 (<a class=new-orange href="https://doi.org/10.12688/f1000research.8211.1" target=_blank>https://doi.org/10.12688/f1000research.8211.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-8211-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=8211 id=track-article-signin-8211 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/8211?target=/articles/5-2105/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=8831 /> <input name=articleId type=hidden value=8211 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Virotherapy: cancer gene therapy at last?</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Alan E. Bilsland<sup>1</sup>,&nbsp;</span><span class="">Pavlina Spiliopoulou<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:j.evans@beatson.gla.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>T. R. Jeffry Evans</span></a><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Alan E. Bilsland<sup>1</sup>,&nbsp;</span><span class="">Pavlina Spiliopoulou<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:j.evans@beatson.gla.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>T. R. Jeffry Evans</span></a><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 30 Aug 2016 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.8211.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Glasgow, G61 1QH, UK<br/> <sup>2</sup> Beatson West of Scotland Cancer Centre, Glasgow, G12 OYN, UK<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16788-15934></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=16789-15935></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach. However, steady progress in vector development and accumulated experience from previous clinical studies has finally led the field to its first licensed therapy. Following a pivotal phase III trial, Imlygic (talimogene laherparepvec/T-Vec) received US approval as a treatment for cutaneous and subcutaneous melanoma in October 2015, followed several weeks later by its European authorisation. These represent the first approvals for an oncolytic virotherapy. Imlygic is an advanced-generation herpesvirus-based vector optimised for oncolytic and immunomodulatory activities. Many other oncolytic agents currently remain in development, providing hope that current success will be followed by other diverse vectors that may ultimately come to constitute a new class of clinical anti-cancer agents. In this review, we discuss some of the key oncolytic viral agents developed in the adenovirus and herpesvirus classes, and the prospects for further enhancing their efficacy by combining them with novel immunotherapeutic approaches. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Cancer gene therapy, oncolytic virus, adenovirus, herpesvirus, cancer immunotherapy, Imlygic, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> T. R. Jeffry Evans (<a href="mailto:j.evans@beatson.gla.ac.uk">j.evans@beatson.gla.ac.uk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> T. R. Jeffry Evans </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by the Glasgow Experimental Cancer Medicine Centre (funded by Cancer Research UK and the Chief Scientist Office, Scotland). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2016 Bilsland AE <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Bilsland AE, Spiliopoulou P and Evans TRJ. Virotherapy: cancer gene therapy at last? [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2105 (<a href="https://doi.org/10.12688/f1000research.8211.1" target=_blank>https://doi.org/10.12688/f1000research.8211.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 30 Aug 2016, <b>5</b>(F1000 Faculty Rev):2105 (<a href="https://doi.org/10.12688/f1000research.8211.1" target=_blank>https://doi.org/10.12688/f1000research.8211.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 30 Aug 2016, <b>5</b>(F1000 Faculty Rev):2105 (<a href="https://doi.org/10.12688/f1000research.8211.1" target=_blank>https://doi.org/10.12688/f1000research.8211.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d12892e182>Introduction</h2><p class="" id=d12892e185>In its broadest sense, the fundamental objective of cancer gene therapy is to transfer therapeutic transgenes specifically to cancer cells while leaving normal cells unharmed. In this paradigm, selectivity can be achieved at any or all of the levels of uptake, transgene expression, or intrinsic tumour sensitivities, and an enormous variety of constructs—coupled with diverse delivery approaches, including viral, bacterial, and chemical vectors—have now been investigated<sup><a href="#ref-1">1</a></sup>. The earliest approaches include gene replacement strategies involving the delivery of a wild-type tumour suppressor gene, which is either lost or deregulated in the target cell. An exemplar of this strategy is restoration of the p53 tumour suppressor that has been widely examined in a variety of preclinical models and clinical studies<sup><a href="#ref-2">2</a>–<a href="#ref-6">6</a></sup>.</p><p class="" id=d12892e199>Blocking the expression of activated oncogenes via antisense approaches has also been seen as attractive<sup><a href="#ref-7">7</a></sup>. However, the absence of positive results in early phase clinical trials has hindered further development of antisense nucleotides, and considerable interest is now focused on optimising oligonucleotide carrier formulations before embarking on further clinical studies<sup><a href="#ref-8">8</a></sup>. Other strategies for “suicide” or cytotoxic gene therapy include cell lysis to enhance tumour immunogenicity or the introduction of genes that amplify tumour sensitivity to drug or radiation therapies<sup><a href="#ref-9">9</a></sup>. These areas of gene therapy have been extensively discussed<sup><a href="#ref-10">10</a></sup>. Although measurable clinical activity has been found in a few “first-generation” approaches, such as adenoviral p53 replacement<sup><a href="#ref-11">11</a></sup>, highly promising results have recently been obtained utilising replicating viral vectors (oncolytic virotherapy) that help maximise gene transduction in tumour cells. In view of recent progress, we focus on this particular field of gene therapy.</p><p class="" id=d12892e222>The door for gene therapy in medicine was perhaps opened in November 2012, when the first human gene treatment, alipogene tiparvovec, was granted approval for patients suffering from familial lipoprotein lipase deficiency, a rare autosomal recessive disorder that leads to recurrent pancreatitis<sup><a href="#ref-12">12</a></sup>. Three years later, the approval of a virotherapy for cancer treatment marked a historic moment for cancer gene therapy in the Western world. The precedent has potentially profound importance for cancer therapeutics, since this approval is likely to represent only the first of a new and diverse class of agents. The concept of treating cancer with pathogenic organisms is now over a century old<sup><a href="#ref-13">13</a></sup>. However, the history of cancer virotherapy has followed cycles of interest and disappointment<sup><a href="#ref-14">14</a></sup>. In the years after the dawn of chemotherapy, as the first anti-cancer agents became available, numerous “oncolytic” viruses were tested for activity<sup><a href="#ref-15">15</a></sup>. Although interest waned after limited clinical successes were achieved, then-recent elucidation of the structure of DNA led even these early investigators to propose modifying viral genomes to rebalance oncolytic versus pathogenic properties<sup><a href="#ref-15">15</a></sup>.</p><p class="" id=d12892e245>Yet, since the first trial of viral-mediated gene transfer into patient tumours<sup><a href="#ref-16">16</a></sup>, realising the promise of gene therapy to provide an arsenal of exquisitely selective and potent anti-cancer agents has remained elusive until now. On 27 October 2015, Imlygic (talimogene laherparepvec/T-Vec) received full US Food and Drug Administration (FDA) approval for the treatment of melanoma, closely followed by European authorisation on 17 December. These approvals were a landmark moment, as the first anti-cancer gene therapy agent approved in the West entered into clinical practice.</p><p class="" id=d12892e253>The remarkable momentum of gene therapy in recent years has been extensively reviewed<sup><a href="#ref-17">17</a>–<a href="#ref-20">20</a></sup>. However, the most significant clinical success stories until now have remained in fields other than cancer. Many approaches suffer from limited vector penetration in tumours, which is often insufficient to produce substantial efficacy<sup><a href="#ref-21">21</a></sup>. Thus, conditionally replicating (oncolytic) vectors have been considered by many to be the best candidates for clinical success. Imlygic is an advanced-generation herpes simplex virus type 1 (HSV1) vector optimised for oncolytic activity and armed with the immunostimulatory granulocyte-macrophage colony-stimulating factor (GM-CSF) gene<sup><a href="#ref-22">22</a></sup>.</p><p class="" id=d12892e271>The immunomodulatory aspect of Imlygic activity may point the way to future successes; recently, growing awareness that anti-tumour immune responses mediate the efficacy of oncolytic agents has drawn cancer gene therapies and immunotherapies closer<sup><a href="#ref-23">23</a>–<a href="#ref-26">26</a></sup>. Indeed, several other oncolytic vectors armed with transgenes to stimulate anti-tumour T-cell responses are currently in development. In this context, another promising approach that has recently demonstrated remarkable clinical activity uses T-lymphocytes engineered with artificial chimeric antigen receptors (T-CARs). These may ultimately prove highly complementary to oncolytic agents.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d12892e284>Oncolytic virotherapy and immunomodulation</h2><p class="" id=d12892e287>Oncolytic virotherapy relies on selective replication of a virus specifically within cancer cells, triggering tumour cell death and vector spread into new cells. A wide range of vector backbones have been investigated, including “naturally oncolytic” organisms such as reovirus<sup><a href="#ref-27">27</a>–<a href="#ref-29">29</a></sup>. However, most agents comprise attenuated variants of well-characterised viruses. Here we focus on adenovirus and herpesvirus, since these backgrounds have undergone the most extensive vector engineering.</p><p class="" id=d12892e297>In these, selective replication is commonly achieved by the deletion of viral genes whose products ordinarily suppress cellular sentinels of the cell cycle, or of anti-viral responses. Replication is then facilitated in tumour cells with inactivation of these pathways; if such checkpoints are inactive, the requirement for a viral suppressor is removed. Alternatively, directing tumour-specific expression of the same viral genes using cancer-specific gene promoter elements achieves similarly restricted replication profiles via silencing viral protein expression in normal cells<sup><a href="#ref-9">9</a>,<a href="#ref-30">30</a></sup>.</p><p class="" id=d12892e307>Adenovirus replication depends initially on the expression of differentially spliced products of the early phase genes adenovirus early region 1A (E1A) and E1B, which together promote S-phase entry, setting the stage for the viral gene expression programme through multiple interactions with cellular transcription machinery. These include induction of transcription factor E2F by negative regulation of the retinoblastoma protein pRb by E1A and inhibition of checkpoint and apoptosis pathways by E1B<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>.</p><p class="" id=d12892e317>The earliest notable oncolytic adenovirus is dl1520/Onyx-015<sup><a href="#ref-33">33</a></sup>. An Ad2/Ad5-hybrid lacking the E1B-55K gene, which acts in part through binding and inactivating p53, dl1520 was originally proposed to replicate selectively in tumour cells lacking p53 function and was originally developed by Onyx Pharmaceuticals (USA)<sup><a href="#ref-34">34</a></sup>. However, this mechanism was widely questioned, and subsequent investigations indicated that late functions of E1B-55K, involving the regulation of translation, are rate limiting for dl1520 replication<sup><a href="#ref-35">35</a></sup>.</p><p class="" id=d12892e333>The agent was safely delivered via both intratumoural<sup><a href="#ref-36">36</a>–<a href="#ref-40">40</a></sup> and intravascular (mainly hepatic arterial) or intraperitoneal routes<sup><a href="#ref-38">38</a>,<a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>, targeting either primary or secondary malignant hepatic disease. As monotherapy, dl1520 showed modest clinical outcomes, mainly in the form of disease stabilisation; however, when combined with cytotoxics in head and neck tumours and colorectal liver metastases, it conferred re-sensitisation to chemotherapy against which these tumours had previously shown resistance<sup><a href="#ref-39">39</a>,<a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>. Correlation between p53 mutation status and response to treatment was not shown, however, amplifying uncertainties regarding the virus’ mechanism of action. The company halted clinical development in 2003; however, the highly related vector H101 was licensed to Sunway Biotech (China) and was approved for use there in 2005.</p><p class="" id=d12892e363>Improvements to replicating adenovirus design have since accumulated, including enhanced strategies for restricting replication and modifications to vector tropism. DNX-2401 (DNAtrix Therapeutics [USA]), formerly known as Ad∆24-RGD, is a second-generation Ad5 vector based on an alternative replication-targeting approach. In the original vector, Ad∆24, the viral E1A gene, reintroduced into a first-generation (E1/E3 deleted) backbone, harbours a 24 bp deletion in the pRb binding site in order to restrict efficient replication to cells with a defective pRb\p16\E2F pathway<sup><a href="#ref-43">43</a></sup>. Subsequently, tropism of the vector was expanded in Ad∆24-RGD, which contains a short peptide harbouring an integrin-binding RGD motif in the viral receptor-binding protein, known as fibre<sup><a href="#ref-44">44</a></sup>.</p><p class="" id=d12892e374>Ad5/Ad2 internalisation involves high-affinity interaction between the terminal “knob” domain of the trimeric fibre and the primary cellular receptor, human coxsackie and adenovirus receptor (hCAR)<sup><a href="#ref-45">45</a>–<a href="#ref-47">47</a></sup>. Subsequently, interactions between cellular αvβ3/αvβ5 integrins and RGD sequence motifs in the capsid protein penton mediate endocytosis<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup>. Hence, modifications to fibre can target Ad2/Ad5 to alternative receptors. hCAR expression is low in some cancer cells and it can also be sequestered in tight junctions between epithelial cells<sup><a href="#ref-50">50</a>–<a href="#ref-52">52</a></sup>. RGD modification provides a tropism extension by re-directing high-affinity binding to integrins.</p><p class="" id=d12892e398>An alternative approach to tropism modification is “pseudotyping”; here, the vector knob domain is wholly replaced by that from a different adenovirus serotype, exhibiting different tropism. For example, Ad3 utilises an alternative receptor to Ad2/Ad5<sup><a href="#ref-53">53</a></sup>. Ad5∆24 vectors expressing the Ad3 knob efficiently infected and replicated in ovarian cancer cells that were resistant to vectors expressing wild-type Ad5 knob<sup><a href="#ref-54">54</a></sup>. Oncos-102/CGTG-102 (Oncos Therapeutics [Finland]) contains the E1A-∆24 mutation, is pseudotyped with Ad3 knob, and is also armed by the addition of the GM-CSF gene in the deleted E3 region in order to promote CD8+ T-cell responses against infected cells.</p><p class="" id=d12892e409>An early trial of CGTG-102 showed that intratumoural or intracavitary delivery in heavily pre-treated patients induced disease responses even when given as a single dose. Furthermore, the vector induced distant anti-tumour immunity<sup><a href="#ref-55">55</a></sup>. After demonstrating 63% disease stabilization in 16 patients, treatment was expanded to 115 trial patients. Serial treatment with CGTG-102 resulted in significantly improved survival (p&lt;0.0001) when compared to single dosing and confirmed the safety of repeat dosing<sup><a href="#ref-24">24</a></sup>. Efficacy results were assessed radiologically, and the patients deriving most benefit were those with soft tissue sarcoma, ovarian cancer, melanoma, mesothelioma, and breast cancer<sup><a href="#ref-56">56</a></sup>. Further improvements to the replication targeting of Ad5∆24 vectors have been made via the third-generation ICOVIR vectors, which combine E1A mutation with tight transcriptional control and translational optimisation<sup><a href="#ref-57">57</a></sup>.</p><p class="" id=d12892e428>Most adenoviral vectors are based on well-characterised laboratory strains representing a restricted range of serotypes. ColoAd1 is a chimeric virus, generated through selection by “directed evolution”, whereby a pool of Ad serotypes from groups B-F are passaged through cell lines of breast, colon, prostate, and pancreatic cancer to allow recombination of potent viral serotypes. ColoAd1 “emerged” through a colon cell line (HT-29)-passaging pool, and is a chimera of Ad11 and Ad3 serotypes belonging to adenovirus Group B<sup><a href="#ref-58">58</a></sup>. When tested on a colon cancer liver-seeding model, it demonstrated increased anti-tumour potency <i>in vivo</i> compared to both Ad5 and dl1520.</p><p class="" id=d12892e439>The group B origin of Colo-Ad1 gives the distinct advantage of an hCAR-independent attachment to cells via principal binding to CD-46 receptor, which is expressed by a variety of tumours such as thyroid, breast, ovarian, endometrial, lung, colorectal, pancreatic, and gastric, and is amplified in higher grade tumours<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>. Proof-of-concept studies are ongoing in bladder/colorectal (NCT02028442) and ovarian (NCT02028117) cancer patients via both systemic and intraperitoneal routes, whilst the combination of ColoAd1 with inhibition of the PD1/PDL1 axis is also planned (NCT02636036).</p><p class="" id=d12892e449>The herpesviruses present a second major vector background that has undergone significant development. HSV1716 (SEPREHVIR, Virttu Biologics [UK]) is an ICP34.5-deleted first-generation oncolytic HSV1 vector. A 759 bp deletion, which conferred avirulence on intracerebral inoculation, was originally identified in a variant of the HSV1 17+ strain. HSV1716 was developed by re-introduction of this spontaneously arising deletion into the wild-type 17+ background<sup><a href="#ref-61">61</a></sup>. The vector was found to replicate selectively in dividing cells, causing cytotoxicity to tumour cells and regression in xenograft models<sup><a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>. Safety was shown following direct intratumoural injection in glioma patients<sup><a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup> and in the intraoperative setting of injection to tumour-adjacent brain tissue after debulking<sup><a href="#ref-66">66</a></sup>.</p><p class="" id=d12892e474>G207 is a second-generation HSV1 vector based on strain F, containing deletions in both loci of ICP34.5 in addition to inactivation of ICP6, thereby disabling the viral ribonucleotide reductase<sup><a href="#ref-67">67</a></sup>. The vector also showed safety in phase I trials in glioblastoma: initially, a single inoculation dose escalation study was performed<sup><a href="#ref-68">68</a></sup>. Subsequently, the vector was tested in a intraoperative setting (pre- and post-resection) and in combination with radiotherapy<sup><a href="#ref-69">69</a>,<a href="#ref-70">70</a></sup>. A further trial (NCT02457845) is planned to assess the safety of G207 alone or with radiation in paediatric patients, but it is not yet recruiting. NV1020 (R7020), another multiply deleted vector based on strain F, contains a 15 kb deletion of the “joint region”, which includes a single copy of ICP34.5, in addition to the U<sub>L</sub>56 gene. This vector is less attenuated than G207.</p><p class="" id=d12892e495>As noted above, Imlygic is the first oncolytic vector to receive approval in the US and Europe. It is an HSV1 vector optimised in several ways<sup><a href="#ref-22">22</a></sup>. The parental strain JS1 was obtained from a new clinical isolate rather than the serially passaged laboratory strains previously utilised in HSV1716 and G207. Unattenuated JS1 demonstrated significantly higher cytotoxic activity than the wild-type 17+ strain in several tumour cell lines. The oncolytic vector was generated by deletion of the ICP34.5 gene in addition to ICP47, which is involved in suppressing antigen presentation<sup><a href="#ref-71">71</a></sup>. Loss of ICP47 therefore promotes an immune response against infected tumour cells, and this aspect is further enhanced through arming with the GM-CSF gene.</p><p class="" id=d12892e506>The OPTiM trial was the first randomised controlled phase III study of an oncolytic agent to have met its efficacy end-point, and thus enough supporting evidence was provided for its recent approval<sup><a href="#ref-72">72</a></sup>. Patients with unresected stage III or IV melanoma and with variable lines of previous treatments were randomised to either intralesional treatment of Imlygic, or systemic treatment with GM-CSF. Clinical efficacy was confirmed with 26.4% of patients experiencing an overall response (complete response [CR] or partial response), and in 16.3% of patients this response lasted for more than 6 months.</p><p class="" id=d12892e513>With a much more favourable toxicity profile than that observed using current immune checkpoint inhibitors, Imlygic also achieved a higher rate of CRs (10% CR rate versus the historic 1–6% rate observed with ipilimumab and pembrolizumab)<sup><a href="#ref-73">73</a>,<a href="#ref-74">74</a></sup>. Both the treatment responses and the survival advantage achieved with intralesional Imlygic were statistically significant in patients with earlier stage than M1b/M1c (without visceral metastases or raised lactate dehydrogenase) with a hazard ratio (HR) for overall survival of 0.57 (p&lt;0.001) when compared to treatment with GM-CSF. This effect should not be attributed only to intralesional oncolysis, as 15% of uninjected visceral lesions reduced their size by ≥50%. Greater benefit, in terms of both response and survival, was also observed in treatment-naïve patients (HR 0.50, p&lt;0.001). The study design minimised treatment discontinuations due to misperceived “pseudo-progressions” allowing patients to be treated for a minimum of 24 weeks if clinically appropriate. Overall, the results confirm the activity of Imlygic in a subset of patients with low-volume injectable melanoma not subjected to multiple lines of treatment. However, it should be noted that systemic GM-CSF is a comparator that lacks a statistically confirmed impact on overall survival<sup><a href="#ref-75">75</a></sup>. Therefore, further studies are needed to validate the role of Imlygic in the melanoma therapeutic algorithm.</p><p class="" id=d12892e528>How can the cancer gene therapy field now build on this success? The development of several agents has previously been incentivised via orphan drug designations (<a href="#T1">Table 1</a>). Most have not yet progressed to pivotal phase III trials, although DNX-2401 may do so in 2016 (<a target=xrefwindow href="http://www.dnatrix.com/pipeline/" id=d12892e533>http://www.dnatrix.com/pipeline/</a>). The approval of Imlygic increases confidence that more approvals could be achieved for vectors that “stay the course”. The wide variety of vector backgrounds being tested is also cause for optimism; this medley of tropisms, lytic cycles, and immunological effects ensures that the agent class is highly diverse.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Oncolytic vectors granted US Food and Drug Administration (FDA) orphan drug designation.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d12892e548 class=n-a></a><thead><a name=d12892e550 class=n-a></a><tr><a name=d12892e552 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d12892e554 class=n-a></a>Agent</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12892e557 class=n-a></a>Vector</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12892e560 class=n-a></a>Company</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12892e563 class=n-a></a>Disease</th><th align=left colspan=1 rowspan=1 valign=top><a name=d12892e566 class=n-a></a>Designation<br class=br>year</th></tr></thead><tbody><a name=d12892e573 class=n-a></a><tr><a name=d12892e575 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12892e577 class=n-a></a>G207</td><td colspan=1 rowspan=1 valign=top><a name=d12892e580 class=n-a></a>Herpes<br class=br>simplex virus</td><td colspan=1 rowspan=1 valign=top><a name=d12892e585 class=n-a></a>Aettis, Inc.</td><td colspan=1 rowspan=1 valign=top><a name=d12892e588 class=n-a></a>Glioma</td><td colspan=1 rowspan=1 valign=top><a name=d12892e591 class=n-a></a>2002</td></tr><tr><a name=d12892e595 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12892e597 class=n-a></a>NTX-010</td><td colspan=1 rowspan=1 valign=top><a name=d12892e600 class=n-a></a>Seneca Valley<br class=br>Virus</td><td colspan=1 rowspan=1 valign=top><a name=d12892e605 class=n-a></a>Neotropix</td><td colspan=1 rowspan=1 valign=top><a name=d12892e608 class=n-a></a>Neuroendocrine<br class=br>tumours</td><td colspan=1 rowspan=1 valign=top><a name=d12892e613 class=n-a></a>2008</td></tr><tr><a name=d12892e617 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12892e619 class=n-a></a>ONCOS-102</td><td colspan=1 rowspan=1 valign=top><a name=d12892e622 class=n-a></a>Adenovirus</td><td colspan=1 rowspan=1 valign=top><a name=d12892e625 class=n-a></a>Oncos<br class=br>Therapeutics</td><td colspan=1 rowspan=1 valign=top><a name=d12892e630 class=n-a></a>Malignant<br class=br>mesothelioma, ovarian<br class=br>cancer, and glioma</td><td colspan=1 rowspan=1 valign=top><a name=d12892e637 class=n-a></a>2013–14</td></tr><tr><a name=d12892e641 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12892e643 class=n-a></a>DNX-2401</td><td colspan=1 rowspan=1 valign=top><a name=d12892e646 class=n-a></a>Adenovirus</td><td colspan=1 rowspan=1 valign=top><a name=d12892e649 class=n-a></a>DNAtrix</td><td colspan=1 rowspan=1 valign=top><a name=d12892e652 class=n-a></a>Glioma</td><td colspan=1 rowspan=1 valign=top><a name=d12892e655 class=n-a></a>2014</td></tr><tr><a name=d12892e659 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d12892e661 class=n-a></a>Reolysin</td><td colspan=1 rowspan=1 valign=top><a name=d12892e664 class=n-a></a>Reovirus</td><td colspan=1 rowspan=1 valign=top><a name=d12892e667 class=n-a></a>Oncolytics<br class=br>Biotech Inc.</td><td colspan=1 rowspan=1 valign=top><a name=d12892e672 class=n-a></a>Glioma, gastric<br class=br>cancer, primary<br class=br>peritoneal cancer,<br class=br>fallopian tube cancer,<br class=br>ovarian cancer, and<br class=br>pancreatic cancer</td><td colspan=1 rowspan=1 valign=top><a name=d12892e685 class=n-a></a>2015</td></tr></tbody></table></div><p class="" id=d12892e692>Imlygic continues development in a number of early phase trials for other solid tumours including pancreatic adenocarcinoma, soft tissue sarcoma, and head and neck squamous cell carcinoma<sup><a href="#ref-76">76</a></sup>. Furthermore, there may be considerable advantage in combining oncolytic agents with other immunomodulatory strategies.<i></i> Combination approaches utilising immune checkpoint inhibitors ipilimumab and pembrolizumab are currently being tested, reflecting a view that efficacy gains could be made through further stimulation of anti-tumour immunity beyond those mechanisms inbuilt in the vector. Preliminary results support a possible synergistic effect in treatment-naïve melanoma patients using Imlygic as a priming agent before immune-induction with ipilimumab<sup><a href="#ref-77">77</a></sup>.</p><p class="" id=d12892e705>Many mechanisms allow tumours to evade natural immunity that would otherwise recognise and eliminate cancer cells<sup><a href="#ref-78">78</a></sup>. Cancer immunotherapy uses various approaches to overcome immune tolerance. In particular, the use of T-cells specifically targeted to tumours has shown considerable clinical promise in recent years. Cytotoxic CD8+ T-cells isolated from cancer patients can recognise tumour-associated antigens via the major histocompatibility complex class I antigen presentation pathway<sup><a href="#ref-79">79</a></sup>. However, <i>in vivo</i>, their anti-tumour activities are blunted. Clinical approaches to enhance T-cell responses have included <i>ex vivo</i> stimulation of antigen-presenting cells with tumour-derived antigens or mRNA<sup><a href="#ref-80">80</a></sup>, systemic administration of synthetic peptides capable of binding class I molecules<sup><a href="#ref-81">81</a></sup>, and pharmacological immune-checkpoint inhibitors<sup><a href="#ref-82">82</a></sup>.</p><p class="" id=d12892e735>An alternative approach circumventing the requirement for antigen processing and presentation involves T-cells transduced <i>ex-vivo</i> with chimeric antigen receptors (T-CARs). The synthetic receptors commonly comprise single-chain antibody fragments serving as the extracellular antigen-recognition domain fused to the CD3ζ transmembrane adaptor signalling domain, with or without additional co-stimulatory domains<sup><a href="#ref-83">83</a></sup>. Together, these serve to signal T-cell activation on binding to cell-surface antigens. T-CARs targeted to CD19 have recently demonstrated significant clinical response rates in patients with haematological malignancies, particularly chronic lymphocytic leukaemia<sup><a href="#ref-84">84</a>–<a href="#ref-87">87</a></sup>. Indeed, sustained responses of several-year duration have been reported in some patients<sup><a href="#ref-88">88</a></sup>. T-CARs are also being developed against a wide range of solid-tumour antigens<sup><a href="#ref-89">89</a></sup>.</p><p class="" id=d12892e760>A particularly interesting avenue for future trials may therefore lie in combining armed immunomodulatory oncolytic agents with T-cell targeting, potentially also alongside immune-checkpoint inhibition. It was recently demonstrated that T-CARs targeted to human epidermal growth factor receptor 2 could act as effective carriers of oncolytic vaccinia or vesicular stomatitis viruses<sup><a href="#ref-90">90</a></sup>. Neither the oncolytic passengers nor the T-cell vehicles appeared to significantly interfere with each other’s activities. However, T-cells are non-permissive for infection by certain vectors, including commonly used adenovirus serotypes, because of low viral receptor expression<sup><a href="#ref-91">91</a></sup>. Nevertheless, alternative approaches could still allow these modalities to be combined: in another study, local delivery to neuroblastoma xenografts of Ad5Δ24 armed with cytokines RANTES and IL15 enhanced infiltration and persistence within the tumour of subsequently delivered T-CARs targeted to the GD2 antigen<sup><a href="#ref-92">92</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d12892e778>Outlook</h2><p class="" id=d12892e781>There is considerable scope for multi-modal immunogenetic therapies to improve further on emerging successes. However, the approval path for advanced biotherapies is not necessarily straightforward<sup><a href="#ref-93">93</a>–<a href="#ref-96">96</a></sup>. Various guidelines have been developed to clarify requirements for viral vector programmes<sup><a href="#ref-97">97</a>,<a href="#ref-98">98</a></sup>. However, to streamline the translation of potentially promising new agents, it is important that researchers adopt a future-focused approach. A recent manifesto calls for a range of practical measures to be embedded in gene therapy programmes. These include using well-defined target-product profiles (as in Pharma), establishing ambitious pre-clinical efficacy cut-offs, planning early for phase I-III clinical studies, and, critically, planning for manufacture and scale-up<sup><a href="#ref-99">99</a></sup>.</p><p class="" id=d12892e802>These general principles should be embedded in programmes and may ease clinical development, but we believe that effective trial design is the core of the issue; fundamentally, late-phase trials must achieve their efficacy endpoints. It remains to be seen if oncolytic vectors can be developed that will be effective when administered systemically. Therefore, delivery routes may continue to dictate those tumours that are tractable. Imlygic is delivered by direct intratumoural injection to cutaneous lesions; intraperitoneal delivery is also an attractive localised route in the setting of ovarian cancer<sup><a href="#ref-100">100</a></sup>.</p><p class="" id=d12892e809>Another key aspect of trial design for gene therapy relates to stratification and pharmacodynamic biomarkers, which will likely prove increasingly critical to the development of gene therapy agents, as for other cancer therapeutics. The absence of suitable stratification markers necessarily leads to a requirement for larger patient groups to identify robust responders. This is clearly undesirable, given that viral vector manufacture and scale-up involve so many variables<sup><a href="#ref-101">101</a></sup>. Indeed, infectivity and growth characteristics of oncolytic agents are individually tailored such that process standardisation for any “vector class” is likely to be problematic. These aspects raise difficulties in predicting production requirements for viral gene therapy regimens, issues that will be compounded in moving to larger efficacy trials. For oncolytics, increasing evidence for the role of anti-tumour immunity in mediating efficacy is leading to the investigation of a range of candidate predictive immunological markers<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a>,<a href="#ref-26">26</a></sup>. On the other hand, given the still-partial mechanistic understanding of some agents, the optimal choice of biomarkers may emerge only during development.</p><p class="" id=d12892e826>Yet, though the hurdles may be higher, the road to effective gene therapies should be seen in the context of the success rate throughout cancer drug development, even for small molecules<sup><a href="#ref-102">102</a></sup>. Taking an optimistic outlook, if the long process of vector development that led us to this point is viewed analogously to lead optimisation in traditional drug development, then gene therapists do not, at least, need to begin with a new scaffold for each target, unlike medicinal chemists. It is fair to suggest that the wilderness years of gene therapy are in the past and that once the optimal vector configurations for cancer applications are understood they will be “selectively replicated”. By combining these with innovative new arming approaches and other modalities, the legacy of Dock<sup><a href="#ref-1">1</a></sup> and others may finally be realised.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d12892e840>Abbreviations</h2><p class="" id=d12892e843>CR, complete response; E1, adenovirus early region 1; GM-CSF, granulocyte-macrophage colony-stimulating factor; hCAR, human coxsackie and adenovirus receptor; HR, hazard ratio; HSV1, herpes simplex virus type 1; T-CARs, chimeric antigen receptor-engineered T-cells.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d12892e1 class=n-a></a><h2 class=main-title id=d13191>Competing interests</h2><p class=metadata-entry><a name=d12892e111 class=n-a></a><p id=d12892e113> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d12892e1 class=n-a></a><h2 class=main-title id=d13193>Grant information</h2><p>This work was supported by the Glasgow Experimental Cancer Medicine Centre (funded by Cancer Research UK and the Chief Scientist Office, Scotland).</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d12892e850 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d13524>References</h2><div class="section ref-list"><a name=d12892e850 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725782856"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e857 class=n-a></a>Chira S, Jackson CS, Oprea I, <i> et al.</i>: Progresses towards safe and efficient gene therapy vectors. <i>Oncotarget.</i> 2015; <b>6</b>(31): 30675–703. <a target=xrefwindow id=d12892e868 href="http://www.ncbi.nlm.nih.gov/pubmed/26362400">PubMed Abstract </a> | <a target=xrefwindow id=d12892e871 href="http://dx.doi.org/10.18632/oncotarget.5169">Publisher Full Text </a> | <a target=xrefwindow id=d12892e875 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4741561">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725782856">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d12892e888 class=n-a></a>Clayman GL, el-Naggar AK, Roth JA, <i> et al.</i>: <i>In vivo</i> molecular therapy with <i>p53</i> adenovirus for microscopic residual head and neck squamous carcinoma. <i>Cancer Res.</i> 1995; <b>55</b>(1): 1–6. <a target=xrefwindow id=d12892e906 href="http://www.ncbi.nlm.nih.gov/pubmed/7805018">PubMed Abstract </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d12892e915 class=n-a></a>Fujiwara T, Grimm EA, Mukhopadhyay T, <i> et al.</i>: Induction of chemosensitivity in human lung cancer cells <i>in vivo</i> by adenovirus-mediated transfer of the wild-type <i>p53</i> gene. <i>Cancer Res.</i> 1994; <b>54</b>(9): 2287–91. <a target=xrefwindow id=d12892e933 href="http://www.ncbi.nlm.nih.gov/pubmed/8162565">PubMed Abstract </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d12892e942 class=n-a></a>Kim J, Hwang ES, Kim JS, <i> et al.</i>: Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse. <i>Cancer Gene Ther.</i> 1999; <b>6</b>(2): 172–8. <a target=xrefwindow id=d12892e953 href="http://www.ncbi.nlm.nih.gov/pubmed/10195884">PubMed Abstract </a> | <a target=xrefwindow id=d12892e956 href="http://dx.doi.org/10.1038/sj.cgt.7700006">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d12892e965 class=n-a></a>Pagliaro LC, Keyhani A, Liu B, <i> et al.</i>: Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. <i>Urol Oncol.</i> 2003; <b>21</b>(6): 456–62. <a target=xrefwindow id=d12892e976 href="http://www.ncbi.nlm.nih.gov/pubmed/14693272">PubMed Abstract </a> | <a target=xrefwindow id=d12892e979 href="http://dx.doi.org/10.1016/S1078-1439(03)00032-2">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d12892e989 class=n-a></a>Spitz FR, Nguyen D, Skibber JM, <i> et al.</i>: <i>In vivo</i> adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. <i>Anticancer Res.</i> 1996; <b>16</b>(6B): 3415–22. <a target=xrefwindow id=d12892e1003 href="http://www.ncbi.nlm.nih.gov/pubmed/9042200">PubMed Abstract </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d12892e1012 class=n-a></a>Merdan T, Kopecek J, Kissel T: Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. <i>Adv Drug Deliv Rev.</i> 2002; <b>54</b>(5): 715–58. <a target=xrefwindow id=d12892e1020 href="http://www.ncbi.nlm.nih.gov/pubmed/12204600">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1023 href="http://dx.doi.org/10.1016/S0169-409X(02)00046-7">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d12892e1032 class=n-a></a>Moreno PM, Pêgo AP: Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. <i>Front Chem.</i> 2014; <b>2</b>: 87. <a target=xrefwindow id=d12892e1040 href="http://www.ncbi.nlm.nih.gov/pubmed/25353019">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1043 href="http://dx.doi.org/10.3389/fchem.2014.00087">Publisher Full Text </a> | <a target=xrefwindow id=d12892e1046 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4196572">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d12892e1055 class=n-a></a>Keith WN, Bilsland A, Hardie M, <i> et al.</i>: Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies. <i>Nat Clin Pract Oncol.</i> 2004; <b>1</b>(2): 88–96. <a target=xrefwindow id=d12892e1066 href="http://www.ncbi.nlm.nih.gov/pubmed/16264826">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1069 href="http://dx.doi.org/10.1038/ncponc0044">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718767470"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e1078 class=n-a></a>Das SK, Menezes ME, Bhatia S, <i> et al.</i>: Gene Therapies for Cancer: Strategies, Challenges and Successes. <i>J Cell Physiol.</i> 2015; <b>230</b>(2): 259–71. <a target=xrefwindow id=d12892e1089 href="http://www.ncbi.nlm.nih.gov/pubmed/25196387">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1092 href="http://dx.doi.org/10.1002/jcp.24791">Publisher Full Text </a> | <a target=xrefwindow id=d12892e1096 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4363073">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718767470">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d12892e1109 class=n-a></a>Chen GX, Zhang S, He XH, <i> et al.</i>: Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. <i>Onco Targets Ther.</i> 2014; <b>7</b>: 1901–9. <a target=xrefwindow id=d12892e1120 href="http://www.ncbi.nlm.nih.gov/pubmed/25364261">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1123 href="http://dx.doi.org/10.2147/OTT.S50483">Publisher Full Text </a> | <a target=xrefwindow id=d12892e1127 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4211860">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d12892e1137 class=n-a></a>Kastelein JJ, Ross CJ, Hayden MR: From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world. <i>Hum Gene Ther.</i> 2013; <b>24</b>(5): 472–8. <a target=xrefwindow id=d12892e1145 href="http://www.ncbi.nlm.nih.gov/pubmed/23578007">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1148 href="http://dx.doi.org/10.1089/hum.2013.063">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d12892e1157 class=n-a></a>Dock G: The Influence of complicating diseases upon leukÆmia.*. <i>The American Journal of the Medical Sciences.</i> 1904; <b>127</b>(4): 563–92. <a target=xrefwindow id=d12892e1165 href="http://insights.ovid.com/american-medical-sciences/ajmeds/1904/04/000/influence-complicating-diseases-upon-leuk-mia/1/00000441">Reference Source</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d12892e1174 class=n-a></a>Kelly E, Russell SJ: History of oncolytic viruses: genesis to genetic engineering. <i>Mol Ther.</i> 2007; <b>15</b>(4): 651–9. <a target=xrefwindow id=d12892e1182 href="http://www.ncbi.nlm.nih.gov/pubmed/17299401">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1185 href="http://dx.doi.org/10.1038/sj.mt.6300108">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d12892e1194 class=n-a></a>Southam CM: Present status of oncolytic virus studies. <i>Trans N Y Acad Sci.</i> 1960; <b>22</b>(8 Series II): 657–73. <a target=xrefwindow id=d12892e1202 href="http://www.ncbi.nlm.nih.gov/pubmed/13833074">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1205 href="http://dx.doi.org/10.1111/j.2164-0947.1960.tb00739.x">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d12892e1214 class=n-a></a>Oldfield EH, Ram Z, Culver KW, <i> et al.</i>: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. <i>Hum Gene Ther.</i> 1993; <b>4</b>(1): 39–69. <a target=xrefwindow id=d12892e1225 href="http://www.ncbi.nlm.nih.gov/pubmed/8384892">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1228 href="http://dx.doi.org/10.1089/hum.1993.4.1-39">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d12892e1237 class=n-a></a>Crystal RG: Adenovirus: the first effective <i>in vivo</i> gene delivery vector. <i>Hum Gene Ther.</i> 2014; <b>25</b>(1): 3–11. <a target=xrefwindow id=d12892e1248 href="http://www.ncbi.nlm.nih.gov/pubmed/24444179">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1251 href="http://dx.doi.org/10.1089/hum.2013.2527">Publisher Full Text </a> | <a target=xrefwindow id=d12892e1255 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3900005">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d12892e1265 class=n-a></a>Glorioso JC: Herpes simplex viral vectors: late bloomers with big potential. <i>Hum Gene Ther.</i> 2014; <b>25</b>(2): 83–91. <a target=xrefwindow id=d12892e1273 href="http://www.ncbi.nlm.nih.gov/pubmed/24502405">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1276 href="http://dx.doi.org/10.1089/hum.2014.2501">Publisher Full Text </a> | <a target=xrefwindow id=d12892e1279 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3922308">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d12892e1288 class=n-a></a>Miller AD: Retroviral vectors: from cancer viruses to therapeutic tools. <i>Hum Gene Ther.</i> 2014; <b>25</b>(12): 989–94. <a target=xrefwindow id=d12892e1296 href="http://www.ncbi.nlm.nih.gov/pubmed/25458252">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1299 href="http://dx.doi.org/10.1089/hum.2014.2542">Publisher Full Text </a> | <a target=xrefwindow id=d12892e1302 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4270132">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d12892e1311 class=n-a></a>Mulligan RC: Development of gene transfer technology. <i>Hum Gene Ther.</i> 2014; <b>25</b>(12): 995–1002. <a target=xrefwindow id=d12892e1319 href="http://www.ncbi.nlm.nih.gov/pubmed/25513845">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1322 href="http://dx.doi.org/10.1089/hum.2014.2543">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d12892e1331 class=n-a></a>Rots MG, Elferink MG, Gommans WM, <i> et al.</i>: An <i>ex vivo</i> human model system to evaluate specificity of replicating and non-replicating gene therapy agents. <i>J Gene Med.</i> 2006; <b>8</b>(1): 35–41. <a target=xrefwindow id=d12892e1345 href="http://www.ncbi.nlm.nih.gov/pubmed/16044485">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1349 href="http://dx.doi.org/10.1002/jgm.815">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d12892e1358 class=n-a></a>Liu BL, Robinson M, Han Z, <i> et al.</i>: ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. <i>Gene Ther.</i> 2003; <b>10</b>(4): 292–303. <a target=xrefwindow id=d12892e1369 href="http://www.ncbi.nlm.nih.gov/pubmed/12595888">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1372 href="http://dx.doi.org/10.1038/sj.gt.3301885">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d12892e1381 class=n-a></a>Hirvinen M, Heiskanen R, Oksanen M, <i> et al.</i>: Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. <i>J Transl Med.</i> 2013; <b>11</b>: 193. <a target=xrefwindow id=d12892e1392 href="http://www.ncbi.nlm.nih.gov/pubmed/23965133">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1395 href="http://dx.doi.org/10.1186/1479-5876-11-193">Publisher Full Text </a> | <a target=xrefwindow id=d12892e1399 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3765225">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d12892e1409 class=n-a></a>Kanerva A, Nokisalmi P, Diaconu I, <i> et al.</i>: Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. <i>Clin Cancer Res.</i> 2013; <b>19</b>(10): 2734–44. <a target=xrefwindow id=d12892e1420 href="http://www.ncbi.nlm.nih.gov/pubmed/23493351">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1423 href="http://dx.doi.org/10.1158/1078-0432.CCR-12-2546">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d12892e1432 class=n-a></a>Pesonen S, Diaconu I, Kangasniemi L, <i> et al.</i>: Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. <i>Cancer Res.</i> 2012; <b>72</b>(7): 1621–31. <a target=xrefwindow id=d12892e1443 href="http://www.ncbi.nlm.nih.gov/pubmed/22323527">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1446 href="http://dx.doi.org/10.1158/0008-5472.CAN-11-3001">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725749944"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e1455 class=n-a></a>Taipale K, Liikanen I, Juhila J, <i> et al.</i>: Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. <i>Mol Ther.</i> 2016; <b>24</b>(1): 175–83. <a target=xrefwindow id=d12892e1466 href="http://www.ncbi.nlm.nih.gov/pubmed/26310629">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1469 href="http://dx.doi.org/10.1038/mt.2015.143">Publisher Full Text </a> | <a target=xrefwindow id=d12892e1473 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4754537">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725749944">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725485743"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e1486 class=n-a></a>Angelova AL, Geletneky K, Nuesch JP, <i> et al.</i>: Tumor Selectivity of Oncolytic Parvoviruses: From <i>in vitro</i> and Animal Models to Cancer Patients. <i>Front Bioeng Biotechnol.</i> 2015; <b>3</b>: 55. <a target=xrefwindow id=d12892e1500 href="http://www.ncbi.nlm.nih.gov/pubmed/25954743">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1504 href="http://dx.doi.org/10.3389/fbioe.2015.00055">Publisher Full Text </a> | <a target=xrefwindow id=d12892e1507 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4406089">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725485743">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726037324"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e1520 class=n-a></a>Kemp V, Hoeben RC, van den Wollenberg DJ: Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus. <i>Viruses.</i> 2016; <b>8</b>(1): pii: E4. <a target=xrefwindow id=d12892e1528 href="http://www.ncbi.nlm.nih.gov/pubmed/26712782">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1531 href="http://dx.doi.org/10.3390/v8010004">Publisher Full Text </a> | <a target=xrefwindow id=d12892e1534 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4728564">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726037324">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725970837"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e1547 class=n-a></a>Al Yaghchi C, Zhang Z, Alusi G, <i> et al.</i>: Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. <i>Immunotherapy.</i> 2015; <b>7</b>(12): 1249–58. <a target=xrefwindow id=d12892e1558 href="http://www.ncbi.nlm.nih.gov/pubmed/26595180">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1561 href="http://dx.doi.org/10.2217/imt.15.90">Publisher Full Text </a> | <a target=xrefwindow id=d12892e1565 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4976866">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725970837">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d12892e1579 class=n-a></a>Dorer DE, Nettelbeck DM: Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. <i>Adv Drug Deliv Rev.</i> 2009; <b>61</b>(7–8): 554–71. <a target=xrefwindow id=d12892e1587 href="http://www.ncbi.nlm.nih.gov/pubmed/19394376">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1590 href="http://dx.doi.org/10.1016/j.addr.2009.03.013">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d12892e1599 class=n-a></a>Berk AJ: Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. <i>Oncogene.</i> 2005; <b>24</b>(52): 7673–85. <a target=xrefwindow id=d12892e1607 href="http://www.ncbi.nlm.nih.gov/pubmed/16299528">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1610 href="http://dx.doi.org/10.1038/sj.onc.1209040">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d12892e1619 class=n-a></a>Flint J, Shenk T: Viral transactivating proteins. <i>Annu Rev Genet.</i> 1997; <b>31</b>: 177–212. <a target=xrefwindow id=d12892e1627 href="http://www.ncbi.nlm.nih.gov/pubmed/9442894">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1630 href="http://dx.doi.org/10.1146/annurev.genet.31.1.177">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d12892e1639 class=n-a></a>Barker DD, Berk AJ: Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. <i>Virology.</i> 1987; <b>156</b>(1): 107–21. <a target=xrefwindow id=d12892e1647 href="http://www.ncbi.nlm.nih.gov/pubmed/2949421">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1650 href="http://dx.doi.org/10.1016/0042-6822(87)90441-7">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d12892e1659 class=n-a></a>Bischoff JR, Kirn DH, Williams A, <i> et al.</i>: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. <i>Science.</i> 1996; <b>274</b>(5286): 373–6. <a target=xrefwindow id=d12892e1670 href="http://www.ncbi.nlm.nih.gov/pubmed/8832876">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1673 href="http://dx.doi.org/10.1126/science.274.5286.373">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d12892e1682 class=n-a></a>O'Shea CC, Soria C, Bagus B, <i> et al.</i>: Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. <i>Cancer Cell.</i> 2005; <b>8</b>(1): 61–74. <a target=xrefwindow id=d12892e1693 href="http://www.ncbi.nlm.nih.gov/pubmed/16023599">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1696 href="http://dx.doi.org/10.1016/j.ccr.2005.06.009">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d12892e1706 class=n-a></a>Galanis E, Okuno SH, Nascimento AG, <i> et al.</i>: Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. <i>Gene Ther.</i> 2005; <b>12</b>(5): 437–45. <a target=xrefwindow id=d12892e1717 href="http://www.ncbi.nlm.nih.gov/pubmed/15647767">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1720 href="http://dx.doi.org/10.1038/sj.gt.3302436">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d12892e1729 class=n-a></a>Habib N, Salama H, Abd El Latif Abu Median A, <i> et al.</i>: Clinical trial of E1B-deleted adenovirus (<i>dl</i>1520) gene therapy for hepatocellular carcinoma. <i>Cancer Gene Ther.</i> 2002; <b>9</b>(3): 254–9. <a target=xrefwindow id=d12892e1743 href="http://www.ncbi.nlm.nih.gov/pubmed/11896441">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1747 href="http://dx.doi.org/10.1038/sj.cgt.7700431">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d12892e1756 class=n-a></a>Habib NA, Sarraf CE, Mitry RR, <i> et al.</i>: E1B-deleted adenovirus (<i>dl</i>1520) gene therapy for patients with primary and secondary liver tumors. <i>Hum Gene Ther.</i> 2001; <b>12</b>(3): 219–26. <a target=xrefwindow id=d12892e1770 href="http://www.ncbi.nlm.nih.gov/pubmed/11177559">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1774 href="http://dx.doi.org/10.1089/10430340150218369">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d12892e1783 class=n-a></a>Khuri FR, Nemunaitis J, Ganly I, <i> et al.</i>: a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. <i>Nat Med.</i> 2000; <b>6</b>(8): 879–85. <a target=xrefwindow id=d12892e1794 href="http://www.ncbi.nlm.nih.gov/pubmed/10932224">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1797 href="http://dx.doi.org/10.1038/78638">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d12892e1806 class=n-a></a>Makower D, Rozenblit A, Kaufman H, <i> et al.</i>: Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. <i>Clin Cancer Res.</i> 2003; <b>9</b>(2): 693–702. <a target=xrefwindow id=d12892e1817 href="http://www.ncbi.nlm.nih.gov/pubmed/12576437">PubMed Abstract </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d12892e1826 class=n-a></a>Reid T, Galanis E, Abbruzzese J, <i> et al.</i>: Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. <i>Cancer Res.</i> 2002; <b>62</b>(21): 6070–9. <a target=xrefwindow id=d12892e1837 href="http://www.ncbi.nlm.nih.gov/pubmed/12414631">PubMed Abstract </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d12892e1847 class=n-a></a>Reid TR, Freeman S, Post L, <i> et al.</i>: Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5–FU/leucovorin. <i>Cancer Gene Ther.</i> 2005; <b>12</b>(8): 673–81. <a target=xrefwindow id=d12892e1858 href="http://www.ncbi.nlm.nih.gov/pubmed/15803147">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1861 href="http://dx.doi.org/10.1038/sj.cgt.7700819">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d12892e1870 class=n-a></a>Fueyo J, Gomez-Manzano C, Alemany R, <i> et al.</i>: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect <i>in vivo</i>. <i>Oncogene.</i> 2000; <b>19</b>(1): 2–12. <a target=xrefwindow id=d12892e1884 href="http://www.ncbi.nlm.nih.gov/pubmed/10644974">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1888 href="http://dx.doi.org/10.1038/sj.onc.1203251">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d12892e1897 class=n-a></a>Suzuki K, Fueyo J, Krasnykh V, <i> et al.</i>: A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. <i>Clin Cancer Res.</i> 2001; <b>7</b>(1): 120–6. <a target=xrefwindow id=d12892e1908 href="http://www.ncbi.nlm.nih.gov/pubmed/11205899">PubMed Abstract </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d12892e1917 class=n-a></a>Bergelson JM, Cunningham JA, Droguett G, <i> et al.</i>: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. <i>Science.</i> 1997; <b>275</b>(5304): 1320–3. <a target=xrefwindow id=d12892e1928 href="http://www.ncbi.nlm.nih.gov/pubmed/9036860">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1931 href="http://dx.doi.org/10.1126/science.275.5304.1320">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d12892e1940 class=n-a></a>Kirby I, Davison E, Beavil AJ, <i> et al.</i>: Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. <i>J Virol.</i> 1999; <b>73</b>(11): 9508–14. <a target=xrefwindow id=d12892e1951 href="http://www.ncbi.nlm.nih.gov/pubmed/10516059">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1954 href="http://www.ncbi.nlm.nih.gov/pmc/articles/112985">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d12892e1963 class=n-a></a>Roelvink PW, Mi Lee G, Einfeld DA, <i> et al.</i>: Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. <i>Science.</i> 1999; <b>286</b>(5444): 1568–71. <a target=xrefwindow id=d12892e1974 href="http://www.ncbi.nlm.nih.gov/pubmed/10567265">PubMed Abstract </a> | <a target=xrefwindow id=d12892e1977 href="http://dx.doi.org/10.1126/science.286.5444.1568">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d12892e1987 class=n-a></a>Wang K, Huang S, Kapoor-Munshi A, <i> et al.</i>: Adenovirus internalization and infection require dynamin. <i>J Virol.</i> 1998; <b>72</b>(4): 3455–8. <a target=xrefwindow id=d12892e1998 href="http://www.ncbi.nlm.nih.gov/pubmed/9525681">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2001 href="http://www.ncbi.nlm.nih.gov/pmc/articles/109852">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d12892e2010 class=n-a></a>Wickham TJ, Mathias P, Cheresh DA, <i> et al.</i>: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. <i>Cell.</i> 1993; <b>73</b>(2): 309–19. <a target=xrefwindow id=d12892e2021 href="http://www.ncbi.nlm.nih.gov/pubmed/8477447">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2024 href="http://dx.doi.org/10.1016/0092-8674(93)90231-E">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d12892e2033 class=n-a></a>Cohen CJ, Shieh JT, Pickles RJ, <i> et al.</i>: The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. <i>Proc Natl Acad Sci U S A.</i> 2001; <b>98</b>(26): 15191–6. <a target=xrefwindow id=d12892e2044 href="http://www.ncbi.nlm.nih.gov/pubmed/11734628">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2047 href="http://dx.doi.org/10.1073/pnas.261452898">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2051 href="http://www.ncbi.nlm.nih.gov/pmc/articles/65005">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d12892e2060 class=n-a></a>Hamdan S, Verbeke CS, Fox N, <i> et al.</i>: The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5–mediated gene transfer in pancreatic cancer cells. <i>Cancer Gene Ther.</i> 2011; <b>18</b>(7): 478–88. <a target=xrefwindow id=d12892e2071 href="http://www.ncbi.nlm.nih.gov/pubmed/21566668">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2074 href="http://dx.doi.org/10.1038/cgt.2011.17">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d12892e2083 class=n-a></a>Strauss R, Sova P, Liu Y, <i> et al.</i>: Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. <i>Cancer Res.</i> 2009; <b>69</b>(12): 5115–25. <a target=xrefwindow id=d12892e2094 href="http://www.ncbi.nlm.nih.gov/pubmed/19491256">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2097 href="http://dx.doi.org/10.1158/0008-5472.CAN-09-0645">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2101 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2738419">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d12892e2110 class=n-a></a>Wang H, Li ZY, Liu Y, <i> et al.</i>: Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. <i>Nat Med.</i> 2011; <b>17</b>(1): 96–104. <a target=xrefwindow id=d12892e2121 href="http://www.ncbi.nlm.nih.gov/pubmed/21151137">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2124 href="http://dx.doi.org/10.1038/nm.2270">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2128 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3074512">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d12892e2138 class=n-a></a>Kanerva A, Zinn KR, Chaudhuri TR, <i> et al.</i>: Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. <i>Mol Ther.</i> 2003; <b>8</b>(3): 449–58. <a target=xrefwindow id=d12892e2149 href="http://www.ncbi.nlm.nih.gov/pubmed/12946318">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2152 href="http://dx.doi.org/10.1016/S1525-0016(03)00200-4">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d12892e2161 class=n-a></a>Cerullo V, Pesonen S, Diaconu I, <i> et al.</i>: Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. <i>Cancer Res.</i> 2010; <b>70</b>(11): 4297–309. <a target=xrefwindow id=d12892e2172 href="http://www.ncbi.nlm.nih.gov/pubmed/20484030">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2175 href="http://dx.doi.org/10.1158/0008-5472.CAN-09-3567">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725395369"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e2184 class=n-a></a>Hemminki O, Parviainen S, Juhila J, <i> et al.</i>: Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy. <i>Oncotarget.</i> 2015; <b>6</b>(6): 4467–81. <a target=xrefwindow id=d12892e2195 href="http://www.ncbi.nlm.nih.gov/pubmed/25714011">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2198 href="http://dx.doi.org/10.18632/oncotarget.2901">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2202 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4414204">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725395369">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d12892e2215 class=n-a></a>Cascallo M, Alonso MM, Rojas JJ, <i> et al.</i>: Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. <i>Mol Ther.</i> 2007; <b>15</b>(9): 1607–15. <a target=xrefwindow id=d12892e2226 href="http://www.ncbi.nlm.nih.gov/pubmed/17579575">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2229 href="http://dx.doi.org/10.1038/sj.mt.6300239">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d12892e2238 class=n-a></a>Kuhn I, Harden P, Bauzon M, <i> et al.</i>: Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. <i>PLoS One.</i> 2008; <b>3</b>(6): e2409. <a target=xrefwindow id=d12892e2249 href="http://www.ncbi.nlm.nih.gov/pubmed/18560559">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2252 href="http://dx.doi.org/10.1371/journal.pone.0002409">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2256 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2423470">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d12892e2265 class=n-a></a>Fishelson Z, Donin N, Zell S, <i> et al.</i>: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. <i>Mol Immunol.</i> 2003; <b>40</b>(2–4): 109–23. <a target=xrefwindow id=d12892e2276 href="http://www.ncbi.nlm.nih.gov/pubmed/12914817">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2279 href="http://dx.doi.org/10.1016/S0161-5890(03)00112-3">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1015109"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e2289 class=n-a></a>Segerman A, Atkinson JP, Marttila M, <i> et al.</i>: Adenovirus type 11 uses CD46 as a cellular receptor. <i>J Virol.</i> 2003; <b>77</b>(17): 9183–91. <a target=xrefwindow id=d12892e2300 href="http://www.ncbi.nlm.nih.gov/pubmed/12915534">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2303 href="http://dx.doi.org/10.1128/JVI.77.17.9183-9191.2003">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2307 href="http://www.ncbi.nlm.nih.gov/pmc/articles/187375">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1015109">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d12892e2319 class=n-a></a>MacLean AR, ul-Fareed M, Robertson L, <i> et al.</i>: Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17<sup>+</sup> between immediate early gene 1 and the 'a' sequence. <i>J Gen Virol.</i> 1991; <b>72</b>(Pt 3): 631–9. <a target=xrefwindow id=d12892e2333 href="http://www.ncbi.nlm.nih.gov/pubmed/1848598">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2337 href="http://dx.doi.org/10.1099/0022-1317-72-3-631">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d12892e2346 class=n-a></a>Brown SM, Harland J, MacLean AR, <i> et al.</i>: Cell type and cell state determine differential <i>in vitro</i> growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. <i>J Gen Virol.</i> 1994; <b>75</b>(Pt 9): 2367–77. <a target=xrefwindow id=d12892e2360 href="http://www.ncbi.nlm.nih.gov/pubmed/8077935">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2364 href="http://dx.doi.org/10.1099/0022-1317-75-9-2367">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d12892e2373 class=n-a></a>Kesari S, Randazzo BP, Valyi-Nagy T, <i> et al.</i>: Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. <i>Lab Invest.</i> 1995; <b>73</b>(5): 636–48. <a target=xrefwindow id=d12892e2384 href="http://www.ncbi.nlm.nih.gov/pubmed/7474937">PubMed Abstract </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d12892e2393 class=n-a></a>Papanastassiou V, Rampling R, Fraser M, <i> et al.</i>: The potential for efficacy of the modified (ICP 34.5<sup>-</sup>)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. <i>Gene Ther.</i> 2002; <b>9</b>(6): 398–406. <a target=xrefwindow id=d12892e2407 href="http://www.ncbi.nlm.nih.gov/pubmed/11960316">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2411 href="http://dx.doi.org/10.1038/sj.gt.3301664">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d12892e2420 class=n-a></a>Rampling R, Cruickshank G, Papanastassiou V, <i> et al.</i>: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. <i>Gene Ther.</i> 2000; <b>7</b>(10): 859–66. <a target=xrefwindow id=d12892e2431 href="http://www.ncbi.nlm.nih.gov/pubmed/10845724">PubMed Abstract </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d12892e2441 class=n-a></a>Harrow S, Papanastassiou V, Harland J, <i> et al.</i>: HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. <i>Gene Ther.</i> 2004; <b>11</b>(22): 1648–58. <a target=xrefwindow id=d12892e2452 href="http://www.ncbi.nlm.nih.gov/pubmed/15334111">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2455 href="http://dx.doi.org/10.1038/sj.gt.3302289">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d12892e2464 class=n-a></a>Mineta T, Rabkin SD, Yazaki T, <i> et al.</i>: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. <i>Nat Med.</i> 1995; <b>1</b>(9): 938–43. <a target=xrefwindow id=d12892e2475 href="http://www.ncbi.nlm.nih.gov/pubmed/7585221">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2478 href="http://dx.doi.org/10.1038/nm0995-938">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d12892e2487 class=n-a></a>Markert JM, Medlock MD, Rabkin SD, <i> et al.</i>: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. <i>Gene Ther.</i> 2000; <b>7</b>(10): 867–74. <a target=xrefwindow id=d12892e2498 href="http://www.ncbi.nlm.nih.gov/pubmed/10845725">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2501 href="http://dx.doi.org/10.1038/sj.gt.3301205">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d12892e2510 class=n-a></a>Markert JM, Liechty PG, Wang W, <i> et al.</i>: Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. <i>Mol Ther.</i> 2009; <b>17</b>(1): 199–207. <a target=xrefwindow id=d12892e2521 href="http://www.ncbi.nlm.nih.gov/pubmed/18957964">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2524 href="http://dx.doi.org/10.1038/mt.2008.228">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2528 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2834981">Free Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718290326"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e2537 class=n-a></a>Markert JM, Razdan SN, Kuo HC, <i> et al.</i>: A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. <i>Mol Ther.</i> 2014; <b>22</b>(5): 1048–55. <a target=xrefwindow id=d12892e2548 href="http://www.ncbi.nlm.nih.gov/pubmed/24572293">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2551 href="http://dx.doi.org/10.1038/mt.2014.22">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2555 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4015243">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718290326">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d12892e2567 class=n-a></a>Goldsmith K, Chen W, Johnson DC, <i> et al.</i>: Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8<sup>+</sup> T cell response. <i>J Exp Med.</i> 1998; <b>187</b>(3): 341–8. <a target=xrefwindow id=d12892e2581 href="http://www.ncbi.nlm.nih.gov/pubmed/9449714">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2585 href="http://dx.doi.org/10.1084/jem.187.3.341">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2588 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2212130">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725516610"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e2598 class=n-a></a>Andtbacka RH, Kaufman HL, Collichio F, <i> et al.</i>: Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. <i>J Clin Oncol.</i> 2015; <b>33</b>(25): 2780–8. <a target=xrefwindow id=d12892e2609 href="http://www.ncbi.nlm.nih.gov/pubmed/26014293">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2612 href="http://dx.doi.org/10.1200/JCO.2014.58.3377">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725516610">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d12892e2625 class=n-a></a>Duad A, Ribas A, Robert C, <i> et al.</i>: Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients with advanced melanoma (MEL) enrolled in KEYNOTE-001. <i>J Clin Oncol.</i> 2015; <b>33</b>(suppl): Abstract 9005. <a target=xrefwindow id=d12892e2636 href="http://meetinglibrary.asco.org/content/148580-156">Reference Source</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/4128956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e2645 class=n-a></a>Hodi FS, O'Day SJ, McDermott DF, <i> et al.</i>: Improved survival with ipilimumab in patients with metastatic melanoma. <i>N Engl J Med.</i> 2010; <b>363</b>(8): 711–23. <a target=xrefwindow id=d12892e2656 href="http://www.ncbi.nlm.nih.gov/pubmed/20525992">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2659 href="http://dx.doi.org/10.1056/NEJMoa1003466">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2663 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3549297">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/4128956">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d12892e2676 class=n-a></a>Kaufman HL, Ruby CE, Hughes T, <i> et al.</i>: Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. <i>J Immunother Cancer.</i> 2014; <b>2</b>: 11. <a target=xrefwindow id=d12892e2687 href="http://www.ncbi.nlm.nih.gov/pubmed/24971166">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2690 href="http://dx.doi.org/10.1186/2051-1426-2-11">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2694 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4072479">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726133764"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e2703 class=n-a></a>Greig SL: Talimogene Laherparepvec: First Global Approval. <i>Drugs.</i> 2016; <b>76</b>(1): 147–54. <a target=xrefwindow id=d12892e2711 href="http://www.ncbi.nlm.nih.gov/pubmed/26620366">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2714 href="http://dx.doi.org/10.1007/s40265-015-0522-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726133764">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726421766"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e2727 class=n-a></a>Puzanov I, Milhem MM, Minor D, <i> et al.</i>: Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. <i>J Clin Oncol.</i> 2016; <b>34</b>(22): 2619–26. <a target=xrefwindow id=d12892e2738 href="http://www.ncbi.nlm.nih.gov/pubmed/27298410">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2741 href="http://dx.doi.org/10.1200/JCO.2016.67.1529">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726421766">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d12892e2755 class=n-a></a>Vinay DS, Ryan EP, Pawelec G, <i> et al.</i>: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. <i>Semin Cancer Biol.</i> 2015; <b>35</b>(Suppl): S185–98. <a target=xrefwindow id=d12892e2766 href="http://www.ncbi.nlm.nih.gov/pubmed/25818339">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2769 href="http://dx.doi.org/10.1016/j.semcancer.2015.03.004">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d12892e2778 class=n-a></a>Kawakami Y, Robbins PF, Rosenberg SA: Human melanoma antigens recognized by T lymphocytes. <i>Keio J Med.</i> 1996; <b>45</b>(2): 100–8. <a target=xrefwindow id=d12892e2786 href="http://www.ncbi.nlm.nih.gov/pubmed/8683899">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2789 href="http://dx.doi.org/10.2302/kjm.45.100">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d12892e2798 class=n-a></a>Vandenberk L, Belmans J, Van Woensel M, <i> et al.</i>: Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. <i>Front Immunol.</i> 2015; <b>6</b>: 663. <a target=xrefwindow id=d12892e2809 href="http://www.ncbi.nlm.nih.gov/pubmed/26834740">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2812 href="http://dx.doi.org/10.3389/fimmu.2015.00663">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2816 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4712296">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d12892e2825 class=n-a></a>Middleton G, Silcocks P, Cox T, <i> et al.</i>: Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(8): 829–40. <a target=xrefwindow id=d12892e2836 href="http://www.ncbi.nlm.nih.gov/pubmed/24954781">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2839 href="http://dx.doi.org/10.1016/S1470-2045(14)70236-0">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1029066"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e2848 class=n-a></a>Parry RV, Chemnitz JM, Frauwirth KA, <i> et al.</i>: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. <i>Mol Cell Biol.</i> 2005; <b>25</b>(21): 9543–53. <a target=xrefwindow id=d12892e2859 href="http://www.ncbi.nlm.nih.gov/pubmed/16227604">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2862 href="http://dx.doi.org/10.1128/MCB.25.21.9543-9553.2005">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2866 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1265804">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1029066">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d12892e2879 class=n-a></a>Maus MV, Grupp SA, Porter DL, <i> et al.</i>: Antibody-modified T cells: CARs take the front seat for hematologic malignancies. <i>Blood.</i> 2014; <b>123</b>(17): 2625–35. <a target=xrefwindow id=d12892e2890 href="http://www.ncbi.nlm.nih.gov/pubmed/24578504">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2893 href="http://dx.doi.org/10.1182/blood-2013-11-492231">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2897 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3999751">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d12892e2907 class=n-a></a>Brentjens RJ, Rivière I, Park JH, <i> et al.</i>: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. <i>Blood.</i> 2011; <b>118</b>(18): 4817–28. <a target=xrefwindow id=d12892e2918 href="http://www.ncbi.nlm.nih.gov/pubmed/21849486">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2921 href="http://dx.doi.org/10.1182/blood-2011-04-348540">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2925 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3208293">Free Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/13096956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e2934 class=n-a></a>Kalos M, Levine BL, Porter DL, <i> et al.</i>: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. <i>Sci Transl Med.</i> 2011; <b>3</b>(95): 95ra73. <a target=xrefwindow id=d12892e2945 href="http://www.ncbi.nlm.nih.gov/pubmed/21832238">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2948 href="http://dx.doi.org/10.1126/scitranslmed.3002842">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2952 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3393096">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/13096956">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d12892e2964 class=n-a></a>Kochenderfer JN, Dudley ME, Feldman SA, <i> et al.</i>: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. <i>Blood.</i> 2012; <b>119</b>(12): 2709–20. <a target=xrefwindow id=d12892e2975 href="http://www.ncbi.nlm.nih.gov/pubmed/22160384">PubMed Abstract </a> | <a target=xrefwindow id=d12892e2978 href="http://dx.doi.org/10.1182/blood-2011-10-384388">Publisher Full Text </a> | <a target=xrefwindow id=d12892e2982 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3327450">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/12661956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e2991 class=n-a></a>Porter DL, Levine BL, Kalos M, <i> et al.</i>: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. <i>N Engl J Med.</i> 2011; <b>365</b>(8): 725–33. <a target=xrefwindow id=d12892e3002 href="http://www.ncbi.nlm.nih.gov/pubmed/21830940">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3005 href="http://dx.doi.org/10.1056/NEJMoa1103849">Publisher Full Text </a> | <a target=xrefwindow id=d12892e3009 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3387277">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/12661956">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d12892e3022 class=n-a></a>Mato A, Porter DL: A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. <i>Blood.</i> 2015; <b>126</b>(4): 478–85. <a target=xrefwindow id=d12892e3030 href="http://www.ncbi.nlm.nih.gov/pubmed/26065655">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3033 href="http://dx.doi.org/10.1182/blood-2015-03-585091">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726661747"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e3042 class=n-a></a>Kakarla S, Gottschalk S: CAR T cells for solid tumors: armed and ready to go? <i>Cancer J.</i> 2014; <b>20</b>(2): 151–5. <a target=xrefwindow id=d12892e3050 href="http://www.ncbi.nlm.nih.gov/pubmed/24667962">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3053 href="http://dx.doi.org/10.1097/PPO.0000000000000032">Publisher Full Text </a> | <a target=xrefwindow id=d12892e3056 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4050065">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726661747">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725600394"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e3070 class=n-a></a>VanSeggelen H, Hammill JA, Dvorkin-Gheva A, <i> et al.</i>: T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice. <i>Mol Ther.</i> 2015; <b>23</b>(10): 1600–10. <a target=xrefwindow id=d12892e3081 href="http://www.ncbi.nlm.nih.gov/pubmed/26122933">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3084 href="http://dx.doi.org/10.1038/mt.2015.119">Publisher Full Text </a> | <a target=xrefwindow id=d12892e3088 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4817919">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725600394">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d12892e3101 class=n-a></a>Schmidt MR, Piekos B, Cabatingan MS, <i> et al.</i>: Expression of a human coxsackie/adenovirus receptor transgene permits adenovirus infection of primary lymphocytes. <i>J Immunol.</i> 2000; <b>165</b>(7): 4112–9. <a target=xrefwindow id=d12892e3112 href="http://www.ncbi.nlm.nih.gov/pubmed/11034423">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3115 href="http://dx.doi.org/10.4049/jimmunol.165.7.4112">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718506444"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12892e3124 class=n-a></a>Nishio N, Diaconu I, Liu H, <i> et al.</i>: Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. <i>Cancer Res.</i> 2014; <b>74</b>(18): 5195–205. <a target=xrefwindow id=d12892e3135 href="http://www.ncbi.nlm.nih.gov/pubmed/25060519">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3138 href="http://dx.doi.org/10.1158/0008-5472.CAN-14-0697">Publisher Full Text </a> | <a target=xrefwindow id=d12892e3142 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4167556">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718506444">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d12892e3155 class=n-a></a>Melchiorri D, Pani L, Gasparini P, <i> et al.</i>: Regulatory evaluation of Glybera in Europe - two committees, one mission. <i>Nat Rev Drug Discov.</i> 2013; <b>12</b>(9): 719. <a target=xrefwindow id=d12892e3166 href="http://www.ncbi.nlm.nih.gov/pubmed/23954897">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3169 href="http://dx.doi.org/10.1038/nrd3835-c1">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d12892e3178 class=n-a></a>Narayanan G, Cossu G, Galli MC, <i> et al.</i>: Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union. <i>Hum Gene Ther Clin Dev.</i> 2014; <b>25</b>(1): 1–6. <a target=xrefwindow id=d12892e3189 href="http://www.ncbi.nlm.nih.gov/pubmed/24649836">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3192 href="http://dx.doi.org/10.1089/humc.2013.230">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d12892e3201 class=n-a></a>Watanabe N, Yano K, Tsuyuki K, <i> et al.</i>: Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera. <i>Mol Ther Methods Clin Dev.</i> 2015; <b>2</b>: 14066. <a target=xrefwindow id=d12892e3212 href="http://www.ncbi.nlm.nih.gov/pubmed/26052534">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3215 href="http://dx.doi.org/10.1038/mtm.2014.66">Publisher Full Text </a> | <a target=xrefwindow id=d12892e3219 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4449026">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d12892e3229 class=n-a></a>Ylä-Herttuala S: Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. <i>Mol Ther.</i> 2012; <b>20</b>(10): 1831–2. <a target=xrefwindow id=d12892e3237 href="http://www.ncbi.nlm.nih.gov/pubmed/23023051">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3240 href="http://dx.doi.org/10.1038/mt.2012.194">Publisher Full Text </a> | <a target=xrefwindow id=d12892e3243 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3464639">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d12892e3252 class=n-a></a>Harmonisation ICo: General principles to address virus and vector shedding ICH Considerations. 2009. <a target=xrefwindow id=d12892e3254 href="http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Consideration_documents/GTDG_Considerations_Documents/ICH_Considerations_Viral-Vector_Shedding_.pdf">Reference Source</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d12892e3263 class=n-a></a>Harmonisation ICo: Oncolytic viruses ICH Considerations. 2009. <a target=xrefwindow id=d12892e3265 href="http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Consideration_documents/GTDG_Considerations_Documents/ICH_Considerations_Oncolytic_Viruses_rev_Sep_17_09.pdf">Reference Source</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d12892e3274 class=n-a></a>Cheever TR, Berkley D, Braun S, <i> et al.</i>: Perspectives on best practices for gene therapy programs. <i>Hum Gene Ther.</i> 2015; <b>26</b>(3): 127–33. <a target=xrefwindow id=d12892e3285 href="http://www.ncbi.nlm.nih.gov/pubmed/25654329">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3288 href="http://dx.doi.org/10.1089/hum.2014.147">Publisher Full Text </a> | <a target=xrefwindow id=d12892e3292 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4367233">Free Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d12892e3301 class=n-a></a>Evans TR, Keith WN: Intra-peritoneal administration of genetic therapies: promises and pitfalls. <i>Minerva Ginecol.</i> 2004; <b>56</b>(6): 529–38. <a target=xrefwindow id=d12892e3309 href="http://www.ncbi.nlm.nih.gov/pubmed/15729205">PubMed Abstract </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d12892e3318 class=n-a></a>Merten OW, Schweizer M, Chahal P, <i> et al.</i>: Manufacturing of viral vectors for gene therapy: Part I. Upstream processing. <i>Pharm Bioprocess.</i> 2014; <b>2</b>(2): 183–203. <a target=xrefwindow id=d12892e3329 href="http://dx.doi.org/10.4155/pbp.14.16">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d12892e3339 class=n-a></a>DiMasi JA, Reichert JM, Feldman L, <i> et al.</i>: Clinical approval success rates for investigational cancer drugs. <i>Clin Pharmacol Ther.</i> 2013; <b>94</b>(3): 329–35. <a target=xrefwindow id=d12892e3350 href="http://www.ncbi.nlm.nih.gov/pubmed/23739536">PubMed Abstract </a> | <a target=xrefwindow id=d12892e3353 href="http://dx.doi.org/10.1038/clpt.2013.117">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Aug 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2105/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2105/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Glasgow, G61 1QH, UK<br/> <sup>2</sup> Beatson West of Scotland Cancer Centre, Glasgow, G12 OYN, UK<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/5-2105/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 30 Aug 2016, 5:2105 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.8211.1">https://doi.org/10.12688/f1000research.8211.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2016 Bilsland AE <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=8831 data-id=8211 data-downloads="" data-views="" data-scholar="10.12688/f1000research.8211.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/5-2105/v1/pdf?article_uuid=2b3ff30f-05fd-4fc8-848a-bf49b3545914" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.8211.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Bilsland AE, Spiliopoulou P and Evans TRJ. Virotherapy: cancer gene therapy at last? [version 1; peer review: 2 approved] <i>F1000Research</i> 2016, <b>5</b>(F1000 Faculty Rev):2105 (<a href="https://doi.org/10.12688/f1000research.8211.1" target=_blank>https://doi.org/10.12688/f1000research.8211.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=8211 id=mobile-track-article-signin-8211 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/8211?target=/articles/5-2105/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=8831 /> <input name=articleId type=hidden value=8211 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Leonard Seymour</strong>, Department of Oncology, University of Oxford, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Leonard Seymour chairs the Scientific Advisory Board for PsiOxus, who are developing ColoAd1. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Hidde J. Haisma</strong>, Department of Pharmaceutical Gene Modulation, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, The Netherlands </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Aug 2016</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/5-2105/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/5-2105/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16788-15934></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=16789-15935></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/5-2105/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>30 Aug 16</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Leonard Seymour</strong>, Department of Oncology, University of Oxford, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Leonard Seymour chairs the Scientific Advisory Board for PsiOxus, who are developing ColoAd1. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Hidde J. Haisma</strong>, Department of Pharmaceutical Gene Modulation, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, The Netherlands </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/5-2105/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/5-2105/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Virotherapy: cancer gene therapy at last?".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/5-2105/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/5-2105/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/5-2105/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Bilsland AE et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/5-2105/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/5-2105",
            templates : {
                twitter : "Virotherapy: cancer gene therapy at last?. Bilsland AE et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/5-2105/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Virotherapy: cancer gene therapy at last?", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Virotherapy: cancer gene therapy at last?", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/8211/8831")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "8831");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "15934": 0,
                           "15935": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "1fbaf063-9caf-4e45-adaa-eb5e9b37e111";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2105.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2105.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/5-2105.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/5-2105.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/5-2105.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>